BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

However, even if the EUA is granted, the chances of the average American receiving Pfizer's COVID-19 vaccine in 2020 is slim. Just days after announcing their COVID-19 vaccine has an efficacy rating of at least 95%, Pfizer has announced that they plan to ask the Food and Drug Administration for emergency use authorization (EUA) today, reports CNBC.

Pfizer COVID-19 vaccine: The timeline now that FDA emergency use has been requested

Shares of Pfizer Inc. gained 1.4% in premarket trading on Friday after it announced plans with BioNTech to submit an application later in the day for an emergency use authorization for their experimental COVID-19 vaccine candidate. BioNTech's stock jumped 6.9% before the market opened.

BioNTech, Pfizer say they plan to submit COVID-19 vaccine application on Friday

Pfizer and BioNTech will on Friday ask regulators to sign off on the emergency use of their coronavirus vaccine, a step that could allow the shot to be given more widely. Pfizer said Friday that it was preparing to file for an emergency use authorization with the US Food and Drug Administration, days after announcing that the vaccine was 95% effective at preventing COVID-19 in a late-stage trial.

Pfizer is about to ask the FDA to authorize its coronavirus vaccine, a critical step before it can be given to more people

Pfizer Inc said on Friday it has applied to U.S. health regulators for emergency use authorization (EUA) of its COVID-19 vaccine, a major step toward providing protection against the new coronavirus for pandemic-weary Americans.

Pfizer applies for U.S. emergency use for COVID-19 vaccine

Moderna

In an attempt to “synchronize” COVID-19 vaccine distribution at par with the U.S., the European Union is deliberating the idea of granting  Pfizer Inc (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), a conditional marketing authorization, Bloomberg reports. What Happened: The European authority is holding constant talks with the U.S. Food and Drug Administration to evaluate and assess the vaccine's efficacy, Ursula von der Leyen, President of the European Commission, told Bloomberg.

BioNtech and Moderna Vaccines May Get Emergency Use Approval In Europe

The FDA process is expected to take a few weeks, and an advisory committee meeting to review the vaccine has been tentatively scheduled for early December.

Pfizer and BioNTech to request emergency authorization from FDA for Covid-19 vaccine.

Its coronavirus vaccine candidate may be among the first to market.

Why Is Everyone Talking About BioNTech Stock?

Zoom Video

Dr. Jeremy Brown knows a lot about pandemics. Here's what he thinks about the exciting trial data coming from Pfizer and BioNTech.

Doctor and Pandemic Expert Shares What Investors Need To Know About Coronavirus Vaccines

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. The submission is based on a vaccine efficacy rate of 95% (p

Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine

Pfizer and BioNTech are submitting an emergency authorisation request in the US which could allow its coronavirus vaccine to be used to treat high-risk populations in the country by mid-December.

Pfizer requests emergency authorisation for coronavirus vaccine in US

BioNTech Chief Executive Ugur Sahin said the company could begin delivering its Pfizer-partnered coronavirus vaccine before Christmas. In response, BioNTech stock popped Thursday.

BioNTech CEO Says Coronavirus Vaccine Could Be Home For Christmas

QIAGEN

QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.

QIAGEN (QGEN), BioNTech to Develop Test to Identify SCCHN

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.

Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%

AstraZeneca

Gilead Sciences

Eli Lilly

Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.

What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?

GlaxoSmithKline

Johnson & Johnson

Novavax

Sanofi

Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.

A Virologist Explains: mRNA Coronavirus Vaccines And What Investors Should Know

U.S. and European regulators could approve Pfizer and BioNTech's experimental COVID-19 vaccine as early as mid-December, the German firm's chief executive said on Wednesday, following the release of positive trial results.

BioNTech says vaccine approval possible in mid-December under ideal conditions

The two companies plan to submit BNT162b2 for Emergency Use Authorization in the very near future.

New Data Shows Higher Efficacy Rate for Pfizer and BioNTech Coronavirus Vaccine Candidate

There's more good news regarding the biotech's coronavirus vaccine candidate.

Here's What's Bumping BioNTech Stock Higher Today

The COVID-19 vaccine duo, Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Pfizer and BioNTech Conclude Late-Stage COVID-19 Trial

Once again, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) are dominating headlines, after the two drugmakers announced their coronavirus vaccine candidate was 95% effective as its final result.

Pfizer, BioNTech Stocks Rise After Final Vaccine Update

Pfizer Inc on Tuesday updated its analysis of the safety profile of its COVID-19 vaccine seen during its large, late-stage trial, saying that 3.8% of participants experienced fatigue after receiving a second dose of the shot.

Pfizer says analysis shows 3.8% of participants experienced fatigue

Drugmaker Pfizer said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, and that it would apply for emergency U.S. authorization within days.

Factbox: Development of Pfizer-BioNTech coronavirus vaccine

Pfizer and BioNTech gained in early Wednesday trading after the companies announced their experimental coronavirus vaccine was 95% effective at protecting patients against COVID-19. The updated figure comes from final analysis of trial data. Preliminary results released on November 9 showed the drug to be 90% effective in the nearly 44,000-person trial. The newest information clears the way for Pfizer and BioNTech to apply for emergency-use authorization from the Food and Drug Administration in a matter of days.

Pfizer and BioNTech climb as 95% vaccine effectiveness tees up application for FDA approval

Pfizer Inc. (NYSE: PFE) andBioNTech SE – ADR (NASDAQ: BNTX) have managed to stay ahead in the vaccine race by a hair's breadth. Within days after Moderna Inc (NASDAQ: MRNA) released its first interim analysis, the U.S.-German combo announced results from the final analysis of their late-stage study of their jointly-developed mRNA vaccine, codenamed BNT162b2.

Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety

But don't let your COVID-19 guard down yet. There's still a long way to go before most people will receive the vaccine.

News for BioNTech SE Stock (BNTX)